News Category
HeartBeam will lead the HEART-CHECK study within a 27.6 million euro European cardiovascular research initiative to evaluate its portable ECG system f...
Helus Pharma has appointed Dr. Suresh Durgam, a veteran CNS drug developer, to its board of directors to support the advancement of its late-stage pip...
Tonix Pharmaceuticals will present its investigational TNX-801 vaccine platform for mpox at the World Vaccine Congress Europe, highlighting its potent...
MindMaze Therapeutics' new real-world evidence shows that home-based neurorehabilitation with MindMotion triples training dose and improves functional...
Quantum BioPharma has received FDA approval to begin Phase 2 clinical testing of Lucid-MS, a potential first-in-class multiple sclerosis therapy that ...
SS Innovations International has submitted its response to the FDA's request for additional information for its SSi Mantra surgical robotic system, po...
MindBio Therapeutics has finished manufacturing its next-generation Edge AI Intoxication Detection Kiosk, a voice-based impairment screening tool that...
MindBio Therapeutics has finished manufacturing its next-generation Edge AI Intoxication Detection Kiosk, a non-invasive voice-based screening tool th...
Retension Pharmaceuticals' upsized $45 million IPO will fund late-stage trials for its hypertension candidate, signaling renewed investor interest in ...
VERAXA Biotech's BiTAC-ADC platform demonstrated significant tumor regression and a differentiated safety profile in preclinical studies, potentially ...
A UK study has identified a potential method to halt lung cancer in its early stages by eliminating 'immune fog,' but residual cancer in some mice sug...
Scinai Immunotherapeutics' CDMO subsidiary signs a $5.1 million development and clinical manufacturing deal with a U.S. biopharma, driving committed c...
VERAXA Biotech presented promising preclinical data for its BiTAC-ADC platform, demonstrating significant tumor regression and a differentiated safety...
Leksum LLC has signed an agreement with the Medical University of Vienna to prepare for first-in-human clinical trials of LK-ICU, a therapy that may p...
A new study reveals a tumor-suppressive axis involving SPRED2, p53, and miR-506-3p that controls cancer stem cell traits in hepatocellular carcinoma, ...
Regentis Biomaterials will present at the 2026 ThinkEquity Conference, showcasing its GelrinC technology and recent clinical and regulatory advancemen...
Newron Pharmaceuticals has received FDA feedback on a clinical hold at U.S. sites for its Phase 3 ENIGMA-TRS 2 trial of evenamide, but remains confide...
Lantern Pharma (NASDAQ: LTRN) will present at the ThinkEquity Conference on Oct. 15, 2026, highlighting its AI-driven RADR platform and oncology pipel...
Helus Pharma will host an investor presentation on October 21, 2026, to highlight its Phase 3 and Phase 2 programs for major depressive disorder and g...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to implement the Phase 2 trial of L...
VERAXA Biotech is implementing FDA-aligned New Approach Methodologies to reduce animal testing in preclinical research, potentially accelerating clini...
Nutriband Inc. has filed a non-provisional utility patent application with the U.S. Patent and Trademark Office aimed at strengthening intellectual pr...
Lantern Pharma has received regulatory and IRB approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300, potentially accelerating de...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business to launch a Phase 2 trial of Lucid-MS, a new m...
VERAXA Biotech (NASDAQ: VRXA) is implementing FDA-aligned New Approach Methodologies to reduce animal testing and accelerate clinical advancement of i...
XORTX Therapeutics is advancing its gout treatment XORLO toward a New Drug Application with the FDA, aiming to address the limitations of current ther...
Quantum BioPharma has entered a Study Start-Up Agreement with Thermo Fisher Scientific to initiate Phase 2 trial activities for Lucid-MS, a potential ...
Telomir Pharmaceuticals (NASDAQ: TELO) has raised approximately $5.6 million in a private investment in public equity (PIPE) financing, with proceeds ...
NanoViricides will present at the NIBA 153rd Investment Conference on Oct. 7, 2026, highlighting its broad-spectrum antiviral NV-387, which is in Phas...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific to implement its Phase 2 trial of Lucid-MS for multiple sclerosi...
A new study reveals lymph-node-like structures in the skull's bone marrow, suggesting the brain has a local immune defense system that could open new ...
Kairos Pharma's ENV-105 combined with apalutamide significantly improved progression-free survival in metastatic castration-resistant prostate cancer,...
AXIM Biotechnologies has submitted a 510(k) to the FDA for a next-generation tear lactoferrin test that aims to provide rapid, objective dry eye diagn...
GeoVax will showcase its next-generation MVA vaccine and manufacturing innovations at a major European vaccine conference, potentially transforming ou...
The Global Markets Forum, a hybrid investor conference on October 7-8, 2026, will feature 20 companies from around the world presenting live to a mass...
NHS England has introduced a groundbreaking brain tumor test that provides genetic results in about two hours instead of eight weeks, potentially acce...
Oncotelic Therapeutics invites scientists and founders to its PDAOAI BIO REBOOT initiative and will present two keynotes at the 10th International Con...
NanoViricides is progressing its Phase II clinical trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus in the Democratic Republic of Congo, with en...
Certified-PEP is highlighting its U.S.-manufactured research peptide portfolio, emphasizing independent batch testing and accessible documentation for...
Philip Ashton-Rickardt, a veteran biotech executive, argues that successful scientific leadership requires the flexibility to abandon or adjust ideas ...
A new approach using blood samples to identify cancer-specific proteins could simplify the development of personalized immunotherapies, but further cl...
Nutriband Inc. celebrates five years on Nasdaq with key milestones in its abuse-deterrent fentanyl patch and outlines upcoming regulatory steps.
Regentis Biomaterials is advancing a regenerative hydrogel, GelrinC, to address the short-term relief but long-term failure problem in knee cartilage ...
HealthLynked Corp. has selected DRCARE247 as its telemedicine partner to embed virtual care into its mobile app and website, aiming to create a seamle...
Stonegate Capital Partners' updated coverage highlights Incannex Healthcare's progress with IHL-42X, which has moved into active clinical execution wi...
Lantern Pharma has completed a $4 million registered direct offering, with potential for an additional $4 million from warrants, to fund its AI-native...
Onco-Innovations advances its preclinical oncology candidate ONC010 with a 300-gram API scale-up, a manufacturing partnership, and CAD$5 million in in...
Quantum BioPharma is advancing its multiple sclerosis drug candidate Lucid-MS into Phase 2 trials while also holding a stake and royalty stream in the...
